We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Cidara Therapeutics, Inc. (CDTX)
Chart Events
Performance Outlook
| Previous Close | 0.7490 |
| Open | 0.7700 |
| Bid | 0.7500 x 1100 |
| Ask | 0.7600 x 800 |
| Day's Range | 0.7500 - 0.7600 |
| 52 Week Range | 0.4600 - 2.1000 |
| Volume | |
| Avg. Volume | 453,953 |
| Market Cap | 68.73M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CDTX
Related Research
- Cidara Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 11/13/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat8 days agoArgus Research
GlobeNewswireCidara Therapeutics Named as a San Diego Metro Area Top Workplace
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by The San Diego Union-Tribune. Cidara was among the top 100 companies and organizations included in the 2023 Top Workplace list. “We are proud to
- GlobeNewswire
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1
GuruFocus.comCidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results
Revenue Totals $12.7 Million, Cash and Cash Equivalents Reach $48.7 Million
- GlobeNewswire
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an update on its corporate activities and product pipeline. “We are proud of the recent advancements of both the REZZAYO program as well as our Cloudbreak® drug-
Simply Wall St.Cidara Therapeutics (NASDAQ:CDTX) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3If approved by the European Medicines Agency, rezafungin could be the first new treatment option in over 10 years for patients with invasive candidiasis.4 SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprie
- GlobeNewswire
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023. The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtua
- GlobeNewswire
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors granted Nicole Davarpanah, M.D., J.D., a new employee, a non-qualified stock option award and restricted stock units (RSUs) fo
- GlobeNewswire
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023. The conference will take place both
- GuruFocus.com
Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc
On September 11, 2023, Leslie Tari, the Chief Scientific Officer of Cidara Therapeutics Inc (NASDAQ:CDTX), sold 18,469 shares of the company.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| CTMX CytomX Therapeutics, Inc. | |||
| CFRX ContraFect Corporation | |||
| CLSD Clearside Biomedical, Inc. | |||
| TCON TRACON Pharmaceuticals, Inc. | |||
| GLYC GlycoMimetics, Inc. |
Similar to CDTX
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ARDX Ardelyx, Inc. | |||
| AKBA Akebia Therapeutics, Inc. | |||
| ZVRA Zevra Therapeutics, Inc. | |||
| PLX Protalix BioTherapeutics, Inc. | |||
| CTMX CytomX Therapeutics, Inc. |
Analyst Price Targets (5)
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/6/2023 | |
| Reiterates | Needham: Buy to Buy | 9/22/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/22/2023 | |
| Reiterates | Needham: Buy to Buy | 9/8/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/7/2023 | |
| Reiterates | HC Wainwright & Co.: to Buy | 8/7/2023 |
Company Profile
6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 73
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
